| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
SFTS is an emerging tick-borne infectious disease. Its fatality is quite high. However, there are no antiviral agents currently approved for clinical use. We have established a safe and rapid assay system for screening selective inhibitors of SFTSV and tested various compounds in the assay system. When ribavirin and favipiravir were examined for their anti-SFTSV activity, their EC50 values were 40.1 ± 16.3 and 25.0 ± 9.3 μM, respectively. Both compounds have already been reported as selective inhibitors of SFTSV replication in vitro. Furthermore, amodiaquine was found to be effective against SFTSV (EC50 = 19.1 ± 5.1 μM).
|
